Drug Companies Have Until Monday to Enter Talks Before Pfizer's Final Offer Expires

LONDON—Large AstraZeneca PLC shareholders on Tuesday voiced opposing views of the company's rejection of Pfizer Inc.'s $120 billion takeover offer, demonstrating the difficulty of coordinating any investor revolt that would be necessary to revive the deal's prospects.

The drug companies have until Monday to enter discussions on a deal, giving any investors dissatisfied with the rejection less than a week to reverse the AstraZeneca...